Carlos Buesa

Oncology

Carlos Buesa, CEO of Oryzon Genomics, discusses exploring how epigenetics is reshaping the landscape of oncology and CNS therapies.

Oncology

At Reuters Pharma USA this week, Boehringer Ingelheim's Vicky Brown spoke with us about the company's recent approval for Hernexeos in NSCLC.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.